India · Delayed Price · Currency is INR Venus Remedies Statistics
Total Valuation
Venus Remedies has a market cap or net worth of INR 24.85 billion. The enterprise value is 23.94 billion.
| Market Cap | 24.85B |
| Enterprise Value | 23.94B |
Important Dates
The last earnings date was Tuesday, May 26, 2026.
| Earnings Date | May 26, 2026 |
| Ex-Dividend Date | Aug 7, 2026 |
Share Statistics
Venus Remedies has 13.37 million shares outstanding. The number of shares has increased by 0.00% in one year.
| Current Share Class | 13.37M |
| Shares Outstanding | 13.37M |
| Shares Change (YoY) | +0.00% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 30.05% |
| Owned by Institutions (%) | 1.13% |
| Float | 6.37M |
Valuation Ratios
The trailing PE ratio is 24.18.
| PE Ratio | 24.18 |
| Forward PE | n/a |
| PS Ratio | 3.23 |
| PB Ratio | 3.74 |
| P/TBV Ratio | 4.36 |
| P/FCF Ratio | 21.04 |
| P/OCF Ratio | 15.96 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.26, with an EV/FCF ratio of 20.27.
| EV / Earnings | 23.30 |
| EV / Sales | 3.11 |
| EV / EBITDA | 16.26 |
| EV / EBIT | 19.69 |
| EV / FCF | 20.27 |
Financial Position
The company has a current ratio of 2.44, with a Debt / Equity ratio of 0.02.
| Current Ratio | 2.44 |
| Quick Ratio | 1.33 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.08 |
| Debt / FCF | 0.11 |
| Interest Coverage | 3,040.25 |
Financial Efficiency
Return on equity (ROE) is 16.78% and return on invested capital (ROIC) is 19.71%.
| Return on Equity (ROE) | 16.78% |
| Return on Assets (ROA) | 9.69% |
| Return on Invested Capital (ROIC) | 19.71% |
| Return on Capital Employed (ROCE) | 17.58% |
| Weighted Average Cost of Capital (WACC) | 5.85% |
| Revenue Per Employee | 5.93M |
| Profits Per Employee | 791,834 |
| Employee Count | 1,298 |
| Asset Turnover | 0.98 |
| Inventory Turnover | 3.37 |
Taxes
In the past 12 months, Venus Remedies has paid 313.70 million in taxes.
| Income Tax | 313.70M |
| Effective Tax Rate | 23.38% |
Stock Price Statistics
The stock price has increased by +312.38% in the last 52 weeks. The beta is 0.30, so Venus Remedies's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | +312.38% |
| 50-Day Moving Average | 1,154.60 |
| 200-Day Moving Average | 774.52 |
| Relative Strength Index (RSI) | 82.22 |
| Average Volume (20 Days) | 29,899 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Venus Remedies had revenue of INR 7.70 billion and earned 1.03 billion in profits. Earnings per share was 76.89.
| Revenue | 7.70B |
| Gross Profit | 3.82B |
| Operating Income | 1.22B |
| Pretax Income | 1.34B |
| Net Income | 1.03B |
| EBITDA | 1.47B |
| EBIT | 1.22B |
| Earnings Per Share (EPS) | 76.89 |
Balance Sheet
The company has 1.03 billion in cash and 124.10 million in debt, with a net cash position of 910.00 million or 68.08 per share.
| Cash & Cash Equivalents | 1.03B |
| Total Debt | 124.10M |
| Net Cash | 910.00M |
| Net Cash Per Share | 68.08 |
| Equity (Book Value) | 6.64B |
| Book Value Per Share | 496.59 |
| Working Capital | 2.33B |
Cash Flow
In the last 12 months, operating cash flow was 1.56 billion and capital expenditures -376.50 million, giving a free cash flow of 1.18 billion.
| Operating Cash Flow | 1.56B |
| Capital Expenditures | -376.50M |
| Depreciation & Amortization | 256.70M |
| Net Borrowing | -25.30M |
| Free Cash Flow | 1.18B |
| FCF Per Share | 88.37 |
Margins
Gross margin is 49.68%, with operating and profit margins of 15.80% and 13.35%.
| Gross Margin | 49.68% |
| Operating Margin | 15.80% |
| Pretax Margin | 17.43% |
| Profit Margin | 13.35% |
| EBITDA Margin | 19.14% |
| EBIT Margin | 15.80% |
| FCF Margin | 15.35% |
Dividends & Yields
This stock pays an annual dividend of 10.00, which amounts to a dividend yield of 0.54%.
| Dividend Per Share | 10.00 |
| Dividend Yield | 0.54% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.00% |
| Shareholder Yield | 0.53% |
| Earnings Yield | 4.14% |
| FCF Yield | 4.75% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |